A biological and pharmacologic phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumors (EORTC 16041).

被引：0
|
作者：
Van Herpen, Carla [1 ]
Fiedler, Walter [2 ]
Marreaud, Sandrine [3 ]
Van Laarhoven, Hanneke [1 ]
Peters, Marlies [1 ]
Govaerts, Anne-Sophie [3 ]
Toma, Salvatore [4 ]
Bordignon, Claudio [4 ]
Heerschap, Arend [1 ]
Punt, Kees [1 ]
机构：
[1] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands
[2] Univ Hamburg Hosp, Hamburg, Germany
[3] Eortc Data Ctr, Brussels, Belgium
[4] Molmed SpA, Milan, Italy
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3457S / 3457S
页数：1
相关论文
共 50 条
  • [11] NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells
    P Di Matteo
    C Hackl
    C Jedeszko
    B Valentinis
    C Bordignon
    C Traversari
    R S Kerbel
    G-P Rizzardi
    British Journal of Cancer, 2013, 109 : 360 - 369
  • [12] A phase I safety and IRK study of the novel vascular targeting agent (VTA), Exherin, in patients with refractory solid tumors stratified according to N-cadherin expression
    Jonker, DJ
    Avruch, L
    Stewart, DJ
    Goel, R
    Goss, G
    Dent, S
    Reaume, MN
    Spencer, TA
    Peters, WP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 214S - 214S
  • [13] Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
    Patricia M. LoRusso
    Shirish M. Gadgeel
    Antoinette Wozniak
    Alan J. Barge
    Helen K. Jones
    Zachary S. DelProposto
    Pamela A. DeLuca
    Jeffrey L. Evelhoch
    Scott A. Boerner
    Catherine Wheeler
    Investigational New Drugs, 2008, 26 : 159 - 167
  • [14] Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
    LoRusso, Patricia M.
    Gadgeel, Shirish M.
    Wozniak, Antoinette
    Barge, Alan J.
    Jones, Helen K.
    DelProposto, Zachary S.
    DeLuca, Pamela A.
    Evelhoch, Jeffrey L.
    Boerner, Scott A.
    Wheeler, Catherine
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (02) : 159 - 167
  • [15] PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS
    Zucali, P. A.
    Santoro, A.
    Simonelli, M.
    De Vincenzo, F.
    Lorenzi, E.
    Rimassa, L.
    Balzarini, L.
    Quagliuolo, V.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 173 - 173
  • [16] Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors.
    Simonelli, M.
    Santoro, A.
    Zucali, P. A.
    Rimassa, L.
    De Vincenzo, F.
    Pressiani, T.
    Tronconi, M. C.
    Carnaghi, C.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [17] A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors
    E. Claire Dees
    Bert H. O’Neil
    Celeste M. Lindley
    Frances Collichio
    Lisa A. Carey
    Jason Collins
    William J. Riordan
    Anastasia Ivanova
    Dixie Esseltine
    Robert Z. Orlowski
    Cancer Chemotherapy and Pharmacology, 2008, 63 : 99 - 107
  • [18] A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors
    Dees, E. Claire
    O'Neil, Bert H.
    Lindley, Celeste M.
    Collichio, Frances
    Carey, Lisa A.
    Collins, Jason
    Riordan, William J.
    Ivanova, Anastasia
    Esseltine, Dixie
    Orlowski, Robert Z.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 63 (01) : 99 - 107
  • [19] Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas
    Mita, A. C.
    Yee, L. K.
    Papadopoulos, K. P.
    Heath, E. I.
    Romero, O.
    Lloyd, G. K.
    Cropp, G.
    Spear, M. A.
    Mita, M. M.
    LoRusso, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [20] Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
    Oh, Do-Youn
    Kim, Tae-Min
    Han, Sae-Won
    Shin, Dong-Yeop
    Lee, Yun Gyoo
    Lee, Keun-Wook
    Kim, Jee Hyun
    Kim, Tae-You
    Jang, In-Jin
    Lee, Jong-Seok
    Bang, Yung-Jue
    CANCER RESEARCH AND TREATMENT, 2016, 48 (01): : 28 - 36
12345